Added to YB: 2023-12-18
Pitch date: 2023-09-18
LQDA [bullish]
Liquidia Corporation
+425.19%
current return
Author Info
No bio for this author
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Market Cap
$2.4B
Pitch Price
$6.51
Price Target
15.00 (-55%)
Dividend
N/A
EV/EBITDA
-23.66
P/E
-19.31
EV/Sales
35.84
Sector
Pharmaceuticals
Category
special_situation
LIQUIDIA CORP - LQDA
LQDA: Yutrepia, an inhaled PAH drug, challenges UTHR's Tyvaso with a more convenient inhaler. Despite legal battles, LQDA prevails. Led by ex-UTHR co-founder, LQDA aims for significant market share. Potential 9x increase to $3.6B market cap in 5 years. PTAB appeal decision in Q1 2024 could drive stock to $15 in 6-12 months. Risks: PTAB loss, go-to-market hurdles.
Read full article (7 min)